SCHEMBL25786244

SCHEMBL25786244

COC(=O)c1c(CN(C)S(=O)(=O)C(F)(F)F)c2c(Br)c(Cl)ccc2n1CCCOc1cc(C)cc2cc(F)ccc12

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAD Q92934 5/20 0.33
BCL2L1 Q07817 3/20 0.33
MCL1 Q07820 2/20 0.32
MARK3 P27448 2/20 0.31
SYK P43405 2/20 0.31
GSK3B P49841 2/20 0.31
PLK1 P53350 2/20 0.31
CAMK2B Q13554 2/20 0.31
MARK2 Q7KZI7 2/20 0.31
MINK1 Q8N4C8 2/20 0.31
SRPK1 Q96SB4 2/20 0.31
HIPK2 Q9H2X6 2/20 0.31
PLK3 Q9H4B4 2/20 0.31
BCL2 P10415 3/20 0.31
CDC7 O00311 1/20 0.31
IRAK1 P51617 1/20 0.31
NEK4 P51957 1/20 0.31
MAP4K2 Q12851 1/20 0.31
CDC42BPA Q5VT25 1/20 0.31
TAOK1 Q7L7X3 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25786243 0.88 MCL1 (0.36) BADBCL2L1MCL1MARK3SYK
SCHEMBL25786235 0.86 BAD (0.39) BADBCL2L1MCL1BCL2PMAIP1
SCHEMBL25786240 0.86 KDM4E (0.37) BADBCL2L1MCL1MARK3SYK
SCHEMBL25786245 0.86 BAD (0.39) BADBCL2L1MCL1BCL2PMAIP1
SCHEMBL25786236 0.85 MARK3 (0.35) BADBCL2L1MCL1MARK3SYK
SCHEMBL25786239 0.82 MAPK8 (0.35) BADBCL2L1MARK3SYKGSK3B
SCHEMBL25293250 0.76 TP53 (0.35) MCL1KDM4EALDH1A1
SCHEMBL25786217 0.75 MARK3 (0.41) MCL1MARK3SYKGSK3BPLK1
SCHEMBL25786221 0.74 MARK3 (0.39) MCL1MARK3SYKGSK3BPLK1
SCHEMBL25786220 0.73 MARK3 (0.37) MCL1MARK3SYKGSK3BPLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691989-B2 Macrocyclic indoles as Mcl-1 inhibitors ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2023-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691989-B2 Macrocyclic indoles as Mcl-1 inhibitors MCL1, BCL2A1, BCL2L1 BAD 20/4885BCL2L1 3/4885MCL1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.